An arabinogalactan from fruits of Lycium barbarum L. inhibits production and aggregation of Aβ42

Oligosaccharides derived from Lycium barbarum ameliorate glycolipid metabolism and modulate the gut microbiota community and the faecal metabolites in a type 2 diabetes mouse model: metabolomic bioinformatic analysis

“…Although LBP activity is closely related to its structure and spatial conformation, its bioactivity mainly depends on the oligosaccharide active fragments. [16][17][18] LBO, obtained by acid hydrolysis combined with enzymatic hydrolysis, can serve as the active centre of LBP. In the past decade, several in vivo studies have shown the efficacy of LBP in lowering blood glucose levels, and the combination of lipid-lowering and antioxidant activity has been considered as the most crucial research development in diabetes.…”

Ultrasonic-assisted enzymatic extraction of Sparassis crispa polysaccharides possessing protective ability against H2O2-induced oxidative damage in mouse hippocampal HT22 cells

“…Several polysaccharides have been reported to possess neuroprotective effects in vitro, possibly due to their good antioxidant activities, such as polysaccharides obtained from Lonicera japonica Thunb., 23 Lycium barbarum L., 24 and Amanita caesarea. 25 In addition, a recent study reported that polysaccharides from S. crispa exhibited protective effects against glutamate-induced toxicity in differentiated PC12 cells, 26 indicating that S. crispa polysaccharides are potential agents for intervention of neurodegenerative diseases.…”

A Novel Pectin-Like Glycopeptide Isolated from the Fruit of Fructus Mori Impedes Aggregation and Production of Aβ42

“…48 Our present study provides novel evidence of an exogenous glycopeptide with the analogical function as the endogenous proteoglycans to the intervention of AD targeting Aβ. In recent years, our lab reported several polysaccharides from traditional Chinese medicines against Aβ 42 aggregation or production; 36,49 however, the monosaccharide constitution, molecular weight, and the structure of the aforementioned polysaccharides are different from FMP-6-S4. We speculate that there would be a more interesting mechanism underlying the anti-AD activity of FMP-6-S4 due to its unique structure.…”